Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aptose Bioscns (APTO)

Aptose Bioscns (APTO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Aptose Presents Highlights From Corporate Event At ASH

Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) released highlights from a corporate event and clinical update today held at the 61 American Society of Hematology (ASH) Annual Meeting and Exposition in...

APTO : 2.56 (-0.39%)
Aptose Appoints Rafael Bejar, M.D., Ph.D., as Chief Medical Officer

Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the appointment of...

APTO : 2.56 (-0.39%)
Aptose to Present at 31st Annual Piper Jaffray Healthcare Conference

Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose...

APTO : 2.56 (-0.39%)
Aptose to Present at BIO-Europe Conference

Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose...

APTO : 2.56 (-0.39%)
Aptose to Present New CG-806 Data at the 2019 ASH Annual Meeting

- Company to Hold Event During ASH -

APTO : 2.56 (-0.39%)
Aptose Reports Results for the Third Quarter Ended September 30, 2019

CG-806 Mutation Agnostic FLT3/BTK Inhibitor and APTO-253 MYC Inhibitor Safely Dose Escalate

APTO : 2.56 (-0.39%)
Aptose To Release Third Quarter Ended September 30, 2019 Financial Results and Hold Conference Call on November 5, 2019

Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and...

APTO : 2.56 (-0.39%)
Aptose to Participate at 5th International Conference on Acute Myeloid Leukemia of the European School of Haematology (ESH)

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today...

APTO : 2.56 (-0.39%)
Aptose to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today...

APTO : 2.56 (-0.39%)
Aptose Reports Results for the Second Quarter Ended June 30, 2019

- APTO-253 Inhibits MYC in AML and MDS Patients in Phase 1 Clinical Trial -

APTO : 2.56 (-0.39%)
Aptose Biosciences to Present at Canaccord Genuity 39th Annual Growth Conference

Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that William G. Rice,...

APTO : 2.56 (-0.39%)
Aptose To Release Second Quarter Ended June 30, 2019 Financial Results and Hold Conference Call on August 6, 2019

Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and...

APTO : 2.56 (-0.39%)
Aptose Doses First CLL Patient in Phase 1 Study of CG-806 and Doses Third Cohort in Phase 1 Study of APTO-253

- CG-806 oral non-covalent pan-FLT3/pan-BTK inhibitor being developed for the treatment of CLL and other B-cell malignancies and for AML -

APTO : 2.56 (-0.39%)
The Zacks Analyst Blog Highlights: Middlesex Water, Howard Hughes, Ubiquiti, Aptose and Aytu

The Zacks Analyst Blog Highlights: Middlesex Water, Howard Hughes, Ubiquiti, Aptose and Aytu

MSEX : 63.37 (+1.31%)
UBNT : 110.59 (+0.18%)
HHC : 115.20 (+1.35%)
APTO : 2.56 (-0.39%)
AYTU : 0.74 (-7.62%)
Bond Yields Plunge Globally on Slowdown Fears: 5 Safe Picks

A growing number of central banks are giving signals for pursuing easy monetary policy in order to raise inflation and generate economic growth.

MSEX : 63.37 (+1.31%)
UBNT : 110.59 (+0.18%)
HHC : 115.20 (+1.35%)
APTO : 2.56 (-0.39%)
AYTU : 0.74 (-7.62%)
Aptose Announces Proposed Public Offering of Common Shares

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), today announced that it has commenced an underwritten public offering of its Common Shares (the "Offering"). In addition, Aptose...

APTO : 2.56 (-0.39%)
Aptose to Present New Preclinical Data for CG-806 at the 24th Congress of The European Hematology Association

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today...

APTO : 2.56 (-0.39%)
Aptose to Present at May Investor Conferences

Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and...

APTO : 2.56 (-0.39%)
APS.TO : 3.37 (-0.59%)
Aptose Announces Commencement of Previously Announced $20.0 Million Common Share Purchase Agreement with Aspire Capital Fund, LLC

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today...

APTO : 2.56 (-0.39%)
APS.TO : 3.37 (-0.59%)
Aptose Reports Results for the First Quarter Ended March 31, 2019

- Patient Dosed at Second Dose Level in APTO-253 Clinical Trial -

APTO : 2.56 (-0.39%)
APS.TO : 3.37 (-0.59%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI +0.46 , AIZ +1.17 , SBAC +0.55 , SO -0.62 , WELL -0.29
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar